|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases activity |
ISO |
chelerythrine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] chelerythrine results in decreased activity of ABCB11 protein |
CTD |
PMID:24014644 |
|
NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein]; chelerythrine inhibits the reaction [Tetrachlorodibenzodioxin results in increased localization of AHR protein] |
CTD |
PMID:10037446 PMID:15364539 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
chelerythrine inhibits the reaction [sodium arsenite inhibits the reaction [Cisplatin results in increased expression of BAX protein]] |
CTD |
PMID:12690470 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP ISO |
chelerythrine inhibits the reaction [sodium arsenite inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]] chelerythrine inhibits the reaction [Resveratrol affects the expression of BCL2 protein] |
CTD |
PMID:12690470 PMID:31151226 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
multiple interactions |
EXP |
chelerythrine inhibits the reaction [Capsaicin results in increased expression of CALCA protein] |
CTD |
PMID:18752301 |
|
NCBI chr 1:184,184,018...184,188,922
Ensembl chr 1:184,184,020...184,188,911
|
|
G |
Casp2 |
caspase 2 |
increases cleavage |
ISO |
chelerythrine results in increased cleavage of CASP2 protein |
CTD |
PMID:26124276 |
|
NCBI chr 4:71,652,358...71,670,228
Ensembl chr 4:71,652,354...71,670,239
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage increases activity |
EXP ISO |
malonic acid inhibits the reaction [chelerythrine results in increased activity of CASP3 protein]; Rotenone inhibits the reaction [chelerythrine results in increased activity of CASP3 protein] Acetylcysteine inhibits the reaction [chelerythrine results in increased cleavage of CASP3 protein]; Dithiothreitol inhibits the reaction [chelerythrine results in increased cleavage of CASP3 protein]; quinoline-val-asp(OMe)-CH2-OPH inhibits the reaction [chelerythrine results in increased cleavage of CASP3 protein]; S-methyl glutathione inhibits the reaction [chelerythrine results in increased cleavage of CASP3 protein] |
CTD |
PMID:21664962 PMID:26124276 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp6 |
caspase 6 |
increases cleavage |
ISO |
chelerythrine results in increased cleavage of CASP6 protein |
CTD |
PMID:26124276 |
|
NCBI chr 2:235,341,326...235,353,715
Ensembl chr 2:235,341,365...235,353,967 Ensembl chr 2:235,341,365...235,353,967
|
|
G |
Casp7 |
caspase 7 |
increases cleavage |
ISO |
chelerythrine results in increased cleavage of CASP7 protein |
CTD |
PMID:26124276 |
|
NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases cleavage increases activity |
EXP ISO |
malonic acid inhibits the reaction [chelerythrine results in increased activity of CASP9 protein]; Rotenone inhibits the reaction [chelerythrine results in increased activity of CASP9 protein] chelerythrine results in increased cleavage of CASP9 protein |
CTD |
PMID:21664962 PMID:26124276 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Casr |
calcium-sensing receptor |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [CASR protein results in increased uptake of Calcium] |
CTD |
PMID:21562303 |
|
NCBI chr11:67,188,204...67,262,261
Ensembl chr11:67,188,630...67,258,771
|
|
G |
Ccn1 |
cellular communication network factor 1 |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [Phenylephrine results in increased expression of CCN1 mRNA] |
CTD |
PMID:15117851 |
|
NCBI chr 2:251,529,354...251,532,312
Ensembl chr 2:251,529,354...251,532,312
|
|
G |
Cftr |
CF transmembrane conductance regulator |
decreases activity |
ISO |
chelerythrine results in decreased activity of CFTR protein |
CTD |
PMID:14744818 |
|
NCBI chr 4:42,693,263...42,860,679
Ensembl chr 4:42,692,836...42,860,676
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
chelerythrine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; chelerythrine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; chelerythrine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein] |
CTD |
PMID:16901605 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [CYP1B1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]; chelerythrine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]; chelerythrine promotes the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]] |
CTD |
PMID:10037446 |
|
NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
EXP |
chelerythrine inhibits the reaction [EDN1 protein results in increased expression of NCF1 protein] |
CTD |
PMID:18436224 |
|
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [EGF protein inhibits the reaction [Acetaldehyde affects the localization of TJP1 protein]]; chelerythrine inhibits the reaction [EGF protein results in decreased susceptibility to Acetaldehyde] |
CTD |
PMID:17991733 |
|
NCBI chr 2:68,820,616...68,895,537
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [Glucose results in increased expression of FN1 protein] |
CTD |
PMID:12388107 |
|
NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
decreases activity |
EXP |
chelerythrine results in decreased activity of G6PD protein |
CTD |
PMID:19429815 |
|
NCBI chr X:156,274,800...156,293,935
Ensembl chr X:156,274,800...156,293,926
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
chelerythrine inhibits the reaction [Acrolein results in increased secretion of GPT protein]; chelerythrine inhibits the reaction [allyl alcohol results in increased secretion of GPT protein] |
CTD |
PMID:12755590 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
multiple interactions |
EXP |
chelerythrine inhibits the reaction [sodium arsenite results in increased expression of HSPA1A protein] |
CTD |
PMID:12690470 |
|
NCBI chr20:4,875,834...4,881,751
Ensembl chr20:4,877,324...4,879,779
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
multiple interactions |
EXP |
chelerythrine inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein] |
CTD |
PMID:16178011 |
|
NCBI chr 9:61,680,529...61,691,202
Ensembl chr 9:61,680,530...61,690,956
|
|
G |
Igf1 |
insulin-like growth factor 1 |
affects activity |
EXP |
chelerythrine affects the activity of IGF1 protein |
CTD |
PMID:11548882 |
|
NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [Acids results in increased expression of IL6 mRNA]; chelerythrine inhibits the reaction [Acids results in increased secretion of IL6 protein] chelerythrine inhibits the reaction [Ethanol results in increased expression of IL6 protein] |
CTD |
PMID:19074641 PMID:24300194 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions |
EXP |
chelerythrine results in decreased phosphorylation of and results in decreased activity of JAK2 protein |
CTD |
PMID:15746188 |
|
NCBI chr 1:247,398,667...247,457,521
Ensembl chr 1:247,398,598...247,458,509
|
|
G |
Kcnd3 |
potassium voltage-gated channel subfamily D member 3 |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [Phenylephrine results in decreased activity of KCND3 protein alternative form] |
CTD |
PMID:11709419 |
|
NCBI chr 2:207,923,775...208,140,727
Ensembl chr 2:207,923,775...208,140,727
|
|
G |
Lmna |
lamin A/C |
increases cleavage |
ISO |
chelerythrine results in increased cleavage of LMNA protein |
CTD |
PMID:26124276 |
|
NCBI chr 2:187,842,884...187,863,552
Ensembl chr 2:187,842,885...187,863,516
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO EXP |
chelerythrine inhibits the reaction [evodiamine results in increased phosphorylation of MAPK1 protein]; chelerythrine inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; chelerythrine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; chelerythrine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK1 protein] chelerythrine inhibits the reaction [Estradiol results in increased activity of MAPK1 protein] chelerythrine inhibits the reaction [CXCL8 protein results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:10037446 PMID:14511371 PMID:15831558 PMID:16713447 PMID:19854188 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO EXP |
chelerythrine inhibits the reaction [CXCL8 protein results in increased phosphorylation of MAPK3 protein] chelerythrine inhibits the reaction [Estradiol results in increased activity of MAPK3 protein] chelerythrine inhibits the reaction [[Lead co-treated with Lipopolysaccharides] results in increased phosphorylation of MAPK3 protein]; chelerythrine inhibits the reaction [evodiamine results in increased phosphorylation of MAPK3 protein]; chelerythrine inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; chelerythrine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; chelerythrine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:10037446 PMID:14511371 PMID:15831558 PMID:16581537 PMID:16713447 PMID:19854188 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
[AG 1879 co-treated with chelerythrine] inhibits the reaction [CXCL8 protein results in increased secretion of MMP9 protein] |
CTD |
PMID:15831558 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [Ethanol results in increased activity of MPO protein] |
CTD |
PMID:24300194 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [Resveratrol affects the expression of MYC protein] |
CTD |
PMID:31151226 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
EXP |
chelerythrine inhibits the reaction [EDN1 protein results in increased expression of NCF1 protein] |
CTD |
PMID:18436224 |
|
NCBI chr12:25,497,104...25,506,300
Ensembl chr12:25,497,104...25,506,300
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
EXP |
[chelerythrine co-treated with tyrphostin 47] inhibits the reaction [Quercetin results in increased expression of NOS3 protein] |
CTD |
PMID:22557973 |
|
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions |
EXP |
chelerythrine inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]; chelerythrine promotes the reaction [2-aminoethoxydiphenyl borate inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]] |
CTD |
PMID:16787574 |
|
NCBI chr 5:164,808,407...164,809,716
Ensembl chr 5:164,808,323...164,809,705
|
|
G |
Nts |
neurotensin |
increases activity |
ISO |
chelerythrine results in increased activity of NTS protein |
CTD |
PMID:18313772 |
|
NCBI chr 7:44,111,594...44,120,998
Ensembl chr 7:44,111,151...44,121,130
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
EXP |
chelerythrine inhibits the reaction [Testosterone results in increased expression of PCNA mRNA] |
CTD |
PMID:21374593 |
|
NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions |
EXP |
chelerythrine inhibits the reaction [Capsaicin results in increased expression of PRKCA protein] |
CTD |
PMID:18752301 |
|
NCBI chr10:96,186,509...96,585,168
Ensembl chr10:96,191,133...96,584,947
|
|
G |
Prkce |
protein kinase C, epsilon |
multiple interactions |
ISO EXP |
chelerythrine inhibits the reaction [Calcium results in increased phosphorylation of PRKCE protein] [chelerythrine results in decreased activity of PRKCE protein] which results in decreased susceptibility to Phenylephrine |
CTD |
PMID:12700091 PMID:21562303 |
|
NCBI chr 6:9,483,400...9,973,396
Ensembl chr 6:9,790,422...9,973,396
|
|
G |
Ptges3 |
prostaglandin E synthase 3 |
increases cleavage |
ISO |
chelerythrine results in increased cleavage of PTGES3 protein |
CTD |
PMID:26124276 |
|
NCBI chr 7:2,479,267...2,497,024
Ensembl chr 7:2,479,311...2,497,013
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [Acids results in increased activity of RELA protein]; chelerythrine inhibits the reaction [Glucose results in increased activity of RELA protein] chelerythrine inhibits the reaction [Ethanol results in increased expression of RELA protein] |
CTD |
PMID:12388107 PMID:19074641 PMID:24300194 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Slc1a1 |
solute carrier family 1 member 1 |
decreases activity multiple interactions |
EXP |
chelerythrine results in decreased activity of SLC1A1 protein chelerythrine inhibits the reaction [Pregabalin results in increased activity of SLC1A1 protein]; chelerythrine inhibits the reaction [Progesterone results in increased activity of SLC1A1 protein] |
CTD |
PMID:17382927 PMID:22511482 PMID:23262392 PMID:23602688 PMID:24355585 |
|
NCBI chr 1:246,955,017...247,035,159
Ensembl chr 1:246,954,980...247,037,056
|
|
G |
Slc5a6 |
solute carrier family 5 member 6 |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [SLC5A6 protein results in increased transport of Biotin] |
CTD |
PMID:15561972 |
|
NCBI chr 6:26,685,823...26,697,110
Ensembl chr 6:26,686,033...26,697,116
|
|
G |
Sptan1 |
spectrin, alpha, non-erythrocytic 1 |
increases cleavage |
ISO |
chelerythrine results in increased cleavage of SPTAN1 protein |
CTD |
PMID:26124276 |
|
NCBI chr 3:8,534,437...8,599,259
Ensembl chr 3:8,534,440...8,599,260
|
|
G |
Stat5a |
signal transducer and activator of transcription 5A |
multiple interactions |
EXP |
chelerythrine results in decreased phosphorylation of and results in decreased activity of STAT5A protein |
CTD |
PMID:15746188 |
|
NCBI chr10:88,764,732...88,789,060
Ensembl chr10:88,764,732...88,789,057
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
EXP |
chelerythrine inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of TH mRNA]; chelerythrine inhibits the reaction [HU 211 results in decreased expression of TH mRNA] |
CTD |
PMID:18992715 |
|
NCBI chr 1:216,073,034...216,080,287
Ensembl chr 1:216,073,031...216,080,287
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [EGF protein inhibits the reaction [Acetaldehyde affects the localization of TJP1 protein]] |
CTD |
PMID:17991733 |
|
NCBI chr 1:126,146,489...126,515,359
Ensembl chr 1:126,146,489...126,227,469
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [Ethanol results in increased expression of TNF protein]; chelerythrine inhibits the reaction [lead acetate promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; chelerythrine inhibits the reaction [lead acetate results in increased expression of TNF protein]; chelerythrine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF protein]; chelerythrine inhibits the reaction [TNF protein results in increased transport of Chlorides]; chelerythrine inhibits the reaction [TNF protein results in increased transport of Potassium] |
CTD |
PMID:10783394 PMID:15302094 PMID:16581537 PMID:24300194 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000 Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnni3 |
troponin I3, cardiac type |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of TNNI3 protein] |
CTD |
PMID:12003851 |
|
NCBI chr 1:72,882,806...72,886,490
Ensembl chr 1:72,882,806...72,886,488
|
|
G |
Tnnt2 |
troponin T2, cardiac type |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of TNNT2 protein] |
CTD |
PMID:12003851 |
|
NCBI chr13:52,662,974...52,680,992
Ensembl chr13:52,662,996...52,680,990
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions |
EXP |
chelerythrine inhibits the reaction [Capsaicin results in increased expression of TRPV1 protein] |
CTD |
PMID:18752301 |
|
NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
affects expression |
ISO |
chelidonine affects the expression of BAX mRNA |
CTD |
PMID:25265580 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
affects expression |
ISO |
chelidonine affects the expression of BCL2 mRNA |
CTD |
PMID:25265580 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions increases metabolic processing |
ISO |
[CYP1A2 protein results in increased metabolism of chelidonine] which results in increased abundance of Glutathione analog |
CTD |
PMID:31102647 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
increases metabolic processing multiple interactions |
ISO |
CYP2C19 protein results in increased metabolism of chelidonine [CYP2C19 protein results in increased metabolism of chelidonine] which results in increased abundance of Glutathione analog |
CTD |
PMID:31102647 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
increases metabolic processing multiple interactions |
ISO |
CYP2D6 protein results in increased metabolism of chelidonine [CYP2D6 protein results in increased metabolism of chelidonine] which results in increased abundance of Glutathione analog |
CTD |
PMID:31102647 |
|
NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
increases metabolic processing multiple interactions |
ISO |
CYP3A4 protein results in increased metabolism of chelidonine [CYP3A4 protein results in increased metabolism of chelidonine] which results in increased abundance of Glutathione analog |
CTD |
PMID:31102647 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Dapk1 |
death associated protein kinase 1 |
affects expression |
ISO |
chelidonine affects the expression of DAPK1 mRNA |
CTD |
PMID:25265580 |
|
NCBI chr17:4,297,038...4,454,941
Ensembl chr17:4,297,224...4,454,778
|
|
G |
Mapt |
microtubule-associated protein tau |
decreases expression |
ISO |
chelidonine results in decreased expression of MAPT protein |
CTD |
PMID:16930453 |
|
NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
|
|
G |
Tert |
telomerase reverse transcriptase |
decreases activity decreases expression |
ISO |
chelidonine results in decreased activity of TERT protein chelidonine results in decreased expression of TERT mRNA |
CTD |
PMID:25265580 |
|
NCBI chr 1:32,250,876...32,275,330
Ensembl chr 1:32,251,714...32,272,476
|
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
dihydrosanguinarine results in increased activity of CASP3 protein |
CTD |
PMID:19346183 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
dihydrosanguinarine results in increased activity of CASP9 protein |
CTD |
PMID:19346183 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases chemical synthesis |
EXP |
NQO1 protein results in increased chemical synthesis of dihydrosanguinarine |
CTD |
PMID:24300172 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
sanguinarine promotes the reaction [AHR protein binds to ARNT protein]; sanguinarine results in increased activity of and affects the localization of AHR protein; sanguinarine results in increased localization of and results in increased activity of AHR protein |
CTD |
PMID:15993743 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions |
ISO |
sanguinarine promotes the reaction [AHR protein binds to ARNT protein] |
CTD |
PMID:15993743 |
|
NCBI chr 2:196,594,178...196,651,486
Ensembl chr 2:196,594,303...196,651,179
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO EXP |
sanguinarine results in increased expression of BAX protein sanguinarine results in increased expression of BAX mRNA; sanguinarine results in increased expression of BAX protein NQO1 protein inhibits the reaction [sanguinarine results in increased expression of BAX mRNA]; NQO1 protein inhibits the reaction [sanguinarine results in increased expression of BAX protein] |
CTD |
PMID:22215411 PMID:24300172 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
multiple interactions |
ISO |
[sanguinarine co-treated with arsenic trioxide] results in increased expression of BBC3 mRNA |
CTD |
PMID:24345465 |
|
NCBI chr 1:78,261,491...78,267,802
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO EXP |
sanguinarine results in decreased expression of BCL2 protein sanguinarine results in decreased expression of BCL2 mRNA; sanguinarine results in decreased expression of BCL2 protein NQO1 protein inhibits the reaction [sanguinarine results in decreased expression of BCL2 mRNA]; NQO1 protein inhibits the reaction [sanguinarine results in decreased expression of BCL2 protein] [sanguinarine results in increased chemical synthesis of Reactive Oxygen Species] which results in decreased expression of BCL2 protein |
CTD |
PMID:22215411 PMID:23660334 PMID:24300172 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l14 |
BCL2 like 14 |
multiple interactions increases expression |
ISO |
[sanguinarine co-treated with arsenic trioxide] results in increased expression of BCL2L14 mRNA sanguinarine results in increased expression of BCL2L14 mRNA |
CTD |
PMID:24345465 |
|
NCBI chr 4:168,139,964...168,183,726
Ensembl chr 4:168,142,271...168,183,096
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions increases cleavage |
ISO |
[Acetylcysteine results in decreased abundance of Reactive Oxygen Species] inhibits the reaction [sanguinarine results in increased cleavage of BID protein] |
CTD |
PMID:23660334 |
|
NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
|
|
G |
Bik |
BCL2-interacting killer |
multiple interactions |
ISO |
[sanguinarine co-treated with arsenic trioxide] results in increased expression of BIK mRNA |
CTD |
PMID:24345465 |
|
NCBI chr 7:124,390,924...124,410,449
Ensembl chr 7:124,391,432...124,410,447
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
multiple interactions |
ISO |
[sanguinarine results in increased chemical synthesis of Reactive Oxygen Species] which results in decreased expression of BIRC2 protein |
CTD |
PMID:23660334 |
|
NCBI chr 8:6,014,014...6,036,668
Ensembl chr 8:6,013,207...6,034,142
|
|
G |
Bnip3l |
BCL2 interacting protein 3 like |
multiple interactions |
ISO |
[sanguinarine co-treated with arsenic trioxide] results in increased expression of BNIP3L mRNA |
CTD |
PMID:24345465 |
|
NCBI chr15:43,643,897...43,667,123
Ensembl chr15:43,643,897...43,667,029
|
|
G |
Card6 |
caspase recruitment domain family, member 6 |
multiple interactions |
ISO |
[sanguinarine co-treated with arsenic trioxide] results in increased expression of CARD6 mRNA |
CTD |
PMID:24345465 |
|
NCBI chr 2:54,810,676...54,824,050
Ensembl chr 2:54,810,110...54,824,033
|
|
G |
Casp1 |
caspase 1 |
multiple interactions increases expression |
ISO |
[sanguinarine co-treated with arsenic trioxide] results in increased expression of CASP1 mRNA sanguinarine results in increased expression of CASP1 mRNA |
CTD |
PMID:24345465 |
|
NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
|
|
G |
Casp3 |
caspase 3 |
decreases expression multiple interactions increases activity |
ISO |
sanguinarine results in decreased expression of CASP3 protein alternative form [sanguinarine co-treated with arsenic trioxide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein; [sanguinarine co-treated with arsenic trioxide] results in increased activity of CASP3 protein; [sanguinarine co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein; [sanguinarine results in increased chemical synthesis of Reactive Oxygen Species] which results in increased activity of CASP3 protein sanguinarine results in increased activity of CASP3 protein |
CTD |
PMID:19135517 PMID:19346183 PMID:20150630 PMID:22215411 PMID:23660334 PMID:24345465 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp4 |
caspase 4 |
multiple interactions |
ISO |
[sanguinarine co-treated with arsenic trioxide] results in increased expression of CASP4 mRNA |
CTD |
PMID:24345465 |
|
NCBI chr 8:2,616,391...2,651,682
Ensembl chr 8:2,635,851...2,651,652
|
|
G |
Casp8 |
caspase 8 |
increases activity multiple interactions |
ISO |
sanguinarine results in increased activity of CASP8 protein [sanguinarine co-treated with arsenic trioxide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; [sanguinarine co-treated with arsenic trioxide] results in increased activity of CASP8 protein; [sanguinarine co-treated with TNFSF10 protein] results in increased activity of CASP8 protein |
CTD |
PMID:19346183 PMID:23660334 PMID:24345465 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
decreases expression multiple interactions increases activity |
ISO |
sanguinarine results in decreased expression of CASP9 protein alternative form [sanguinarine results in increased chemical synthesis of Reactive Oxygen Species] which results in increased activity of CASP9 protein sanguinarine results in increased activity of CASP9 protein |
CTD |
PMID:19135517 PMID:19346183 PMID:22215411 PMID:23660334 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
[9,10-Dimethyl-1,2-benzanthracene co-treated with [Tetradecanoylphorbol Acetate co-treated with sanguinarine]] results in decreased activity of CAT protein; [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] co-treated with sanguinarine] results in decreased activity of CAT protein |
CTD |
PMID:20691676 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
sanguinarine results in increased expression of CDKN1A protein |
CTD |
PMID:15981203 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cldn2 |
claudin 2 |
decreases expression |
ISO |
sanguinarine results in decreased expression of CLDN2 protein |
CTD |
PMID:19063874 |
|
NCBI chr X:111,122,552...111,133,188
Ensembl chr X:111,122,552...111,137,769
|
|
G |
Cldn3 |
claudin 3 |
decreases expression |
ISO |
sanguinarine results in decreased expression of CLDN3 protein |
CTD |
PMID:19063874 |
|
NCBI chr12:21,831,341...21,832,813
Ensembl chr12:21,831,342...21,832,813
|
|
G |
Cldn4 |
claudin 4 |
decreases expression |
ISO |
sanguinarine results in decreased expression of CLDN4 protein |
CTD |
PMID:19063874 |
|
NCBI chr12:24,761,210...24,763,008
Ensembl chr12:24,761,210...24,763,005
|
|
G |
Cldn5 |
claudin 5 |
decreases expression |
ISO |
sanguinarine results in decreased expression of CLDN5 protein |
CTD |
PMID:19063874 |
|
NCBI chr11:86,356,292...86,357,718
Ensembl chr11:86,356,294...86,357,718
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity increases expression increases activity |
ISO EXP |
sanguinarine results in decreased activity of CYP1A1 protein sanguinarine results in increased expression of CYP1A1 mRNA; sanguinarine results in increased expression of CYP1A1 protein sanguinarine results in increased activity of CYP1A1 protein |
CTD |
PMID:15993743 PMID:24300172 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression increases activity |
ISO |
sanguinarine results in increased expression of CYP1B1 mRNA sanguinarine results in increased activity of CYP1B1 protein |
CTD |
PMID:15993743 |
|
NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
|
|
G |
Dedd2 |
death effector domain containing 2 |
multiple interactions |
ISO |
[sanguinarine co-treated with arsenic trioxide] results in increased expression of DEDD2 mRNA |
CTD |
PMID:24345465 |
|
NCBI chr 1:82,073,024...82,089,028
Ensembl chr 1:82,072,544...82,088,275
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions increases expression decreases expression |
ISO |
sanguinarine promotes the reaction [Reactive Oxygen Species results in increased activity of EGR1 protein] sanguinarine results in increased expression of EGR1 protein sanguinarine results in decreased expression of EGR1 protein |
CTD |
PMID:23660334 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
[sanguinarine co-treated with arsenic trioxide] results in increased expression of FAS mRNA |
CTD |
PMID:24345465 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
[sanguinarine co-treated with arsenic trioxide] results in increased expression of FASLG mRNA |
CTD |
PMID:24345465 |
|
NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
|
|
G |
Ggt1 |
gamma-glutamyltransferase 1 |
increases expression |
ISO |
sanguinarine results in increased expression of GGT1 protein |
CTD |
PMID:15981203 |
|
NCBI chr20:14,019,723...14,045,781
Ensembl chr20:14,019,723...14,025,068
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
[9,10-Dimethyl-1,2-benzanthracene co-treated with [Tetradecanoylphorbol Acetate co-treated with sanguinarine]] results in decreased activity of GSR protein; [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] co-treated with sanguinarine] results in decreased activity of GSR protein |
CTD |
PMID:20691676 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions increases expression |
ISO |
sanguinarine inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate]; sanguinarine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of GSTP1 mRNA]; sanguinarine inhibits the reaction [TNF protein results in increased expression of GSTP1 mRNA] sanguinarine results in increased expression of GSTP1 protein |
CTD |
PMID:15313406 PMID:15981203 PMID:23769903 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Hal |
histidine ammonia lyase |
multiple interactions |
ISO |
[9,10-Dimethyl-1,2-benzanthracene co-treated with [Tetradecanoylphorbol Acetate co-treated with sanguinarine]] results in decreased activity of HAL protein; [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] co-treated with sanguinarine] results in decreased activity of HAL protein |
CTD |
PMID:20691676 |
|
NCBI chr 7:34,326,087...34,356,413
Ensembl chr 7:34,326,087...34,356,413
|
|
G |
Hpgds |
hematopoietic prostaglandin D synthase |
decreases activity |
ISO |
sanguinarine results in decreased activity of HPGDS protein |
CTD |
PMID:25603235 |
|
NCBI chr 4:95,945,356...95,970,666
Ensembl chr 4:95,946,025...95,970,666
|
|
G |
Ltb |
lymphotoxin beta |
increases expression multiple interactions |
ISO |
sanguinarine results in increased expression of LTB mRNA [sanguinarine co-treated with arsenic trioxide] results in increased expression of LTB mRNA |
CTD |
PMID:24345465 |
|
NCBI chr20:5,184,631...5,186,476
Ensembl chr20:5,184,515...5,186,503 Ensembl chr20:5,184,515...5,186,503
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
sanguinarine results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [sanguinarine results in increased phosphorylation of MAPK1 protein]; pyrazolanthrone inhibits the reaction [sanguinarine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:19135517 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [sanguinarine results in increased phosphorylation of MAPK3 protein]; pyrazolanthrone inhibits the reaction [sanguinarine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:19135517 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions increases phosphorylation |
ISO |
pyrazolanthrone inhibits the reaction [sanguinarine results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:19135517 |
|
NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions increases phosphorylation |
ISO |
pyrazolanthrone inhibits the reaction [sanguinarine results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:19135517 |
|
NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases expression |
ISO |
sanguinarine results in decreased expression of MMP2 mRNA; sanguinarine results in decreased expression of MMP2 protein |
CTD |
PMID:19063874 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression |
ISO |
sanguinarine results in decreased expression of MMP9 mRNA; sanguinarine results in decreased expression of MMP9 protein |
CTD |
PMID:19063874 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Nfkbiz |
NFKB inhibitor zeta |
increases expression |
ISO |
sanguinarine results in increased expression of NFKBIZ mRNA |
CTD |
PMID:24345465 |
|
NCBI chr11:47,243,342...47,271,487
Ensembl chr11:47,243,342...47,271,487
|
|
G |
Nlrp1a |
NLR family, pyrin domain containing 1A |
multiple interactions increases expression |
ISO |
[sanguinarine co-treated with arsenic trioxide] results in increased expression of NLRP1 mRNA sanguinarine results in increased expression of NLRP1 mRNA |
CTD |
PMID:24345465 |
|
NCBI chr10:57,692,474...57,747,608
Ensembl chr10:57,692,474...57,822,498
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
decreases expression increases reduction multiple interactions |
ISO EXP |
sanguinarine results in decreased expression of NQO1 mRNA; sanguinarine results in decreased expression of NQO1 protein NQO1 protein results in increased reduction of sanguinarine NQO1 protein inhibits the reaction [sanguinarine results in decreased expression of BCL2 mRNA]; NQO1 protein inhibits the reaction [sanguinarine results in decreased expression of BCL2 protein]; NQO1 protein inhibits the reaction [sanguinarine results in increased expression of BAX mRNA]; NQO1 protein inhibits the reaction [sanguinarine results in increased expression of BAX protein] |
CTD |
PMID:22021338 PMID:24300172 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
multiple interactions |
ISO |
[sanguinarine co-treated with arsenic trioxide] results in increased expression of PMAIP1 mRNA |
CTD |
PMID:24345465 |
|
NCBI chr18:62,159,128...62,179,635
Ensembl chr18:62,174,670...62,181,102
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
ISO |
[sanguinarine co-treated with arsenic trioxide] results in increased expression of PYCARD mRNA |
CTD |
PMID:24345465 |
|
NCBI chr 1:199,438,029...199,439,062
Ensembl chr 1:199,437,832...199,439,210
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
decreases expression |
ISO |
sanguinarine results in decreased expression of SNAI1 protein |
CTD |
PMID:19063874 |
|
NCBI chr 3:164,274,710...164,279,199
Ensembl chr 3:164,274,710...164,279,378
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
sanguinarine inhibits the reaction [TNF protein results in increased expression of GSTP1 mRNA] |
CTD |
PMID:15313406 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000 Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfrsf1b |
TNF receptor superfamily member 1B |
multiple interactions |
ISO |
[sanguinarine co-treated with arsenic trioxide] results in increased expression of TNFRSF1B mRNA |
CTD |
PMID:24345465 |
|
NCBI chr 5:163,136,390...163,167,299
Ensembl chr 5:163,136,390...163,167,299
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions increases expression |
ISO |
[sanguinarine co-treated with arsenic trioxide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein; [sanguinarine co-treated with arsenic trioxide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; [sanguinarine co-treated with arsenic trioxide] results in increased expression of TNFSF10 mRNA; [sanguinarine co-treated with TNFSF10 protein] results in increased activity of CASP8 protein; [sanguinarine co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein; TNFSF10 protein results in increased susceptibility to [arsenic trioxide co-treated with sanguinarine] sanguinarine results in increased expression of TNFSF10 mRNA |
CTD |
PMID:24345465 |
|
NCBI chr 2:113,008,008...113,026,899
Ensembl chr 2:113,007,549...113,026,899
|
|
G |
Tyr |
tyrosinase |
multiple interactions |
ISO |
[9,10-Dimethyl-1,2-benzanthracene co-treated with [Tetradecanoylphorbol Acetate co-treated with sanguinarine]] results in decreased activity of TYR protein; [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] co-treated with sanguinarine] results in decreased activity of TYR protein |
CTD |
PMID:20691676 |
|
NCBI chr 1:151,012,598...151,106,802
Ensembl chr 1:151,012,598...151,106,802
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions |
ISO |
[sanguinarine results in increased chemical synthesis of Reactive Oxygen Species] which results in decreased expression of XIAP protein |
CTD |
PMID:23660334 |
|
NCBI chr X:128,409,425...128,455,786
Ensembl chr X:128,409,472...128,453,000
|
|